Daiichi Sankyo takes option on diabetes stem cell start-up
Astellas scores first US blood cancer approval with Xospata
FDA grants leukaemia drug ‘breakthrough’ status
ASCO 2018 – Monday 4th June: BMS tries different tack as Merck & Co locks out lung cancer I/O
Trading in shares of Daiichi Sankyo was suspended yesterday.
AZ tried to buy Daiichi Sankyo last year – report
Label gives guidance in use when restoring normal heart rhythm
Daiichi Sankyo anticoagulant gains EU label boost
Japanese R&D investment could follow EMA out of UK – experts.
Nissan stays in UK – but will Japanese pharma?